4//SEC Filing
Douglas Earl Martin 4
Accession 0001593968-23-001226
CIK 0001737287other
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 6:57 PM ET
Size
8.7 KB
Accession
0001593968-23-001226
Insider Transaction Report
Form 4
Douglas Earl Martin
SVP, General Counsel
Transactions
- Award
Common Stock
2023-08-14+326,876→ 435,834 total - Award
Stock Option (Right to Buy)
2023-08-14+960,854→ 960,854 totalExercise: $4.13Exp: 2033-08-14→ Common Stock (960,854 underlying) - Award
Common Stock
2023-08-14+108,958→ 108,958 total
Footnotes (2)
- [F1]Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028.
- [F2]25% of the shares subject to the stock option shall vest on August 14, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Documents
Issuer
Allogene Therapeutics, Inc.
CIK 0001737287
Entity typeother
Related Parties
1- filerCIK 0001362155
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 6:57 PM ET
- Size
- 8.7 KB